The Use of Total Artificial Heart With Example of Cases for End-Stage Heart Failure Therapy

29th Turkish Cardiology Congress of the Turkish-Society-of-Cardiology (TSC) with International Participation -- OCT 26-29, 2013 -- Antalya, TURKEYWOS: 000329858400098Turkish Soc Cardio

Diltiazem added blood cardioplegia and myocardial protection

Amaç: Bu çalıışmanın amacı Ca++ antagonisti olan diltiazemin kardiyoplejik solüsyona eklenmesinin myokard korunmasındaki etkilerinin araıştırılmasıdır. Yöntem: Aortakoroner bypass operasyonu uygulanan 30 elektif hasta, kontrol ve çalıışma grubu olarak 15 er kiışilik 2 gruba ayrıldı. Kontrol grubunda yaış ortalaması (56.8±10.11), çalıışma grubunda ise (60.20±10.44) idi. Her iki grup arasında koroner lezyon, X- klemp, Kardiyopulmoner bypass (CPB) süreleri açısından fark saptanmadı. Kardiyopleji iki gruba da antegrad yoldan verildi. Hemodinamik ölçümler ve enzim tayinleri CPB öncesi ve sonrasında ayrı ayrı değerlendirildi. Bulgular: Kardiyoplejik solüsyona eklenen diltiazem ile hemodinamik parametrelerden CO ve CI deki 1. ve 6. saatlerdeki düışük bulundu(p<0,05).Buna rağmen, stroke volüm indeks ve sol ventriküler stroke work indeks de değiışiklik saptanmadı. CPK-MB düzeylerinde 6.- 12. ve 24. saatlerde diltiazem verilen grupta anlamlı düışme saptanmııştır(p<0,05). ıki grup arasında hastaların hemodinamisinde klinik olarak fark gözlenmemiıştir. Sonuç: Bu bulgular, kardiyoplejik solüsyona eklenen diltiazem ile hemodinamik parametrelerde bozulma olmadığı ve CPK-MB düzeylerinde anlamlı düışme saptanmıış olması, kalsiyum antagonistlerinden diltiazemin kardiyoplejik solüsyona eklenmesinin miyokardial koruma ve reperfüzyon hasarını önlemede önemli katkısı bulunduğunu göstermektedir.Objective: The aim of this prospective study was to demonstrate the effect of diltiazem, a calcium channel blocker, as an additive to cardioplegic solution in myocardial protection. Methods: Thirty patients who underwent coronary artery bypass grafting on an elective basis were divided into two groups: control group and diltiazem group (n=15, each). Diltiazem was added to the blood cardioplegic solution in the diltiazem group. Mean age was 56.8+10.11 years in the control group and 60.20+10.44 in the diltiazem group. There was no difference in the extent of coronary artery disease, cross-clamp time, cardiopulmonary bypass (CPB) time between the two groups. Cardioplegic solution was delivered antegradely. Hemodynamics and blood enzyme levels were measured before and following CPB. Results: In the diltiazem group, cardiac output and cardiac index was found to be lower in postoperative 1st and 6th hours (p<0.05). However, there was no difference in stroke volume index and left ventricular stroke work index values. Blood creatine kinase MB (CK-MB) isoenzyme levels were found to be lower in the diltiazem group in 6th, 12th, and 24th hours postoperatively (p<0.05). Patient hemodynamics did not differ clinically in either group. Conclusion: These results demonstrate the beneficial effects of diltiazem addition to blood cardioplegic solution on myocardial protection as evidenced by lower levels of CK-MB in the postoperative period

Propensity score-based analysis of long-term follow-up in patients supported with durable centrifugal left ventricular assist devices:the EUROMACS analysis

OBJECTIVES: The HeartWare HVAD (HW) and the HeartMate3 (HM3) are presently the most commonly used continuous-flow left ventricular assist devices worldwide. We compared the outcomes of patients supported with either of these 2 devices based on data from the EUROMACS (European Registry for Patients with Mechanical Circulatory Support). METHODS: A retrospective analysis of the survival and complications profile in propensity score-matched adult patients enrolled in the EUROMACS between 01 January 2016 and 01 September 2020 and supported with either an HW or HM3. Matching included demographic parameters, severity of cardiogenic shock and risk-modifying end-organ parameters that impact long-term survival. Survival on device and major postoperative adverse events were analysed. RESULTS: Following 1:1 propensity score matching, each group consisted of 361 patients. Patients were well balanced (<0.1 standardized mean difference). The median follow-up was similar in both groups [396 (interquartile range (IQR) 112-771) days for HW and 376 (IQR 100-816) days for HM3]. The 2-year survival was similar in both groups [HW: 61% 95% confidence interval (CI) (56-67%) vs HM3: 68% 95% CI (63-73%) (stratified hazard ratio for mortality: 1.13 95% CI (0.83-1.54), P = 0.435].The cumulative incidence for combined major adverse events and unexpected readmissions was similar in both groups [subdistribution hazard ratio (SHR) 1.0 (0.84-1.21), P = 0.96]. Patients in the HW group demonstrated a higher risk of device malfunction [SHR 2.44 (1.45-3.71), P < 0.001], neurological dysfunction [SHR 1.29 (1.02-1.61), P = 0.032] and intracranial bleeding [SHR 1.76 (1.13-2.70), P = 0.012]. CONCLUSIONS: Mid-term survival in both groups was similar in a propensity-matched analysis. The risk of device malfunction, neurological dysfunction and intracranial bleeding was significantly higher in HW patients

Outcomes of patients after successful left ventricular assist device explantation: a EUROMACS study

Aims: Sufficient myocardial recovery with the subsequent explantation of a left ventricular assist device (LVAD) occurs in approximately 1–2% of the cases. However, follow-up data about this condition are scarcely available in the literature. This study aimed to report the long-term outcomes and clinical management following LVAD explantation. Methods and results: An analysis of the European Registry for Patients with Mechanical Circulatory Support was performed to identify all adult patients with myocardial recovery and successful explantation. Pre-implant characteristics were retrieved and compared with the non-recovery patients. The follow-up data after explantation were collected via a questionnaire. A Kaplan–Meier analysis for freedom of the composite endpoint of death, heart transplantation, LVAD reimplantion, or heart failure (HF) relapse was conducted. A total of 45 (1.4%) cases with myocardial recovery resulting in successful LVAD explantation were identified. Compared with those who did not experience myocardial recovery, the explanted patients were younger (44 vs. 56 years, P < 0.001), had a shorter duration of cardiac disease (P < 0.001), and were less likely to have ischaemic cardiomyopathy (9% vs. 41.8%, P < 0.001). Follow-up after explantation could be acquired in 28 (62%) cases. The median age at LVAD implantation was 43 years (inter-quartile range: 29–52),

The European Registry for Patients with Mechanical Circulatory Support (EUROMACS)

OBJECTIVES: A second paediatric report has been generated from the European Registry for Patients with Mechanical Circulatory Support (EUROMACS). The purpose of EUROMACS, which is operated by the European Association for Cardio-Thoracic Surgery, is to gather data related to durable mechanical circulatory support for scientific purposes and to publish reports with respect to the course of mechanical circulatory support therapy. Since the first report issued, efforts to increase compliance and participation have been extended. Additionally, the data provided the opportunity to analyse patients of younger age and lower weight. METHODS: Participating hospitals contributed pre-, peri- and long-term postoperative data on mechanical circulatory support implants to the registry. Data for all implants in paediatric patients (≤19 years of age) performed from 1 January 2000 to 1 July 2019 were analysed. This report includes updates of patient characteristics, implant frequency, outcome (including mortality rates, transplants and recovery rates) as well as adverse events including neurological dysfunction, device malfunction, major infection and bleeding. RESULTS: Twenty-nine hospitals contributed 398 registered implants in 353 patients (150 female, 203 male) to the registry. The most frequent aetiology of heart failure was any form of cardiomyopathy (61%), followed by congenital heart disease and myocarditis (16.4% and 16.1%, respectively). Competing outcomes analysis revealed that a total of 80% survived to transplant or recovery or are ongoing; at the 2-year follow-up examination, 20% died while on support. At 12 months, 46.7% received transplants, 8.7% were weaned from their device and 18.5% died. The 3-month adverse events rate was 1.69 per patient-year for device malfunction including pump exchange, 0.48 for major bleeding, 0.64 for major infection and 0.78 for neurological events. CONCLUSIONS: The overall survival rate was 81.5% at 12 months following ventricular assist device implant. The comparison of survival rates of the early and later eras shows no significant difference. A focus on specific subgroups showed that survival was less in patients of younger age (<1 year of age) (P = 0.01) and lower weight (<20 kg) (P = 0.015). Transplant rates at 6 months contin

2019 EACTS Expert Consensus on long-term mechanical circulatory support

Long-term mechanical circulatory support (LT-MCS) is an important treatment modality for patients with severe heart failure. Different devices are available, and many-sometimes contradictory-observations regarding patient selection, surgical techniques, perioperative management and follow-up have been published. With the growing expertise in this field, the European Association for Cardio-Thoracic Surgery (EACTS) recognized a need for a structured multidisciplinary consensus about the approach to patients with LT-MCS. However, the evidence published so far is insufficient to allow for generation of meaningful guidelines complying with EACTS requirements. Instead, the EACTS presents an expert opinion in the LT-MCS field. This expert opinion addresses patient evaluation and preoperative optimization as well as management of cardiac and non-cardiac comorbidities. Further, extensive operative implantation techniques are summarized and evaluated by leading experts, depending on both patient characteristics and device selection. The faculty recognized that postoperative management is multidisciplinary and includes aspects of intensive care unit stay, rehabilitation, ambulatory care, myocardial recovery and end-of-life care and mirrored this fact in this paper. Additionally, the opinions of experts on diagnosis and management of adverse events including bleeding, cerebrovascular accidents and device malfunction are presented. In this expert consensus, the evidence for the complete management from patient selection to end-of-life care is carefully reviewed with the aim of guiding clinicians in optimizing management of patients considered for or supported by an LT-MCS device

Aortik homogreft viabilitesinin biyokimyasal yöntemlerle değerlendirilmesi (deneysel çalışma)

Bu tezin, veri tabanı üzerinden yayınlanma izni bulunmamaktadır. Yayınlanma izni olmayan tezlerin basılı kopyalarına Üniversite kütüphaneniz aracılığıyla (TÜBESS üzerinden) erişebilirsiniz.[Abstarct Not Available